Drugs / IgM-enriched Intravenous Immunoglobulins
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01867645 Comparator | Dec 2004 → Apr 2009 | polyneuropathy | Medical University of Vienna | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IgM-enriched Intravenous Immunoglobulins | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01867645 ↗ |
| Known as | Pentaglobin | “IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion” NCT01867645 ↗ |
| Modality | Protein / enzyme biologic | “IgM-enriched intravenous immunoglobulin (IVIG)” NCT01867645 ↗ |
| Route | Intravenous | “as a continuous intravenous infusion” NCT01867645 ↗ |